Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.05
Bid: 2.90
Ask: 3.20
Change: -0.05 (-1.61%)
Spread: 0.30 (10.345%)
Open: 3.10
High: 3.10
Low: 3.05
Prev. Close: 3.10
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

Tue, 19th Mar 2024 19:47

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

TMT Investments PLC - venture capital investor in high-growth technology companies - Reports net asset value per share of USD6.62 in the year ending December 31, rising 3.3% from USD6.41 the year prior. Total NAV rose to USD208.1 million from USD201.7 million. Explains improvement was mainly as a result of the upward revaluation of Backblaze and Collectly during the period. "With no financial debt and cash and cash equivalent reserves of USD11.0 million," TMT is "well positioned to ride out the current market volatility and to continue making investments and realising full and partial disposals when the right opportunities present themselves."

----------

Ten Lifestyle Group PLC - London-based lifestyle and travel services company - Issues trading update for six months to February 29. Expects to report half year net revenue of around GBP30.9 million, unchanged from last year, or up 4% at constant currency. Says active members continue to grow, up 13% to 356,000 from 316,000 last year. Explains the group secured and launched some significant contracts during the period that are expected to generate revenue in the second half of the year. Adjusted earnings before interest, tax, depreciation and amortisation is expected to be around GBP5.3 million, up from GBP5.0 million last year. At the end of the first half, says cash and cash equivalents were GBP8.0 million, compared to GBP8.2 million at the previous year-end.

----------

First Class Metals PLC - Ontario, Canada-focused exploration company - Signs sixty day exclusivity agreement with Emerald Geological Services Ltd in respect of an earn-in to the McInnes Lake Property in Ontario. Chief Executive Marc Sale comments: "This is an exciting development for FCM greenfield exploration opportunities on a property which potentially contains the same structure that is present at Red Lake. The lack of previous systematic or comprehensive exploration in a favourable geological setting presents realistic expectation for a significant discovery." Pays CAD5,000, around GBP2,897, for the exclusivity period.

----------

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Starts search for a chief executive officer to lead the next stage of growth. Expects the process may take a number of months, during which period Suzy Dilly will remain as CEO. As part of the re-structuring process, Dilly and the board will consider potential alternative roles. In addition, Adrian de Courcey joins the board as non-executive director.

----------

Atlantic Lithium Ltd - lithium development company, currently focused on developing the Ewoyaa project on the Ghanaian coast - Announces further broad and high-grade assay results from resource drilling completed at the Ewoyaa lithium project in Ghana. Notes multiple high-grade and broad extensional drill intersections reported at the new Dog-Leg target. Describes results at Dog-Leg as "significant". Points out drilling has intersected shallow dipping, near surface mineralised pegmatite bodies with true thicknesses up to 35m outside of the mineral resource estimate, proving potential for significant resource growth. Plans to advance the drilling programme to be undertaken in 2024. A mineral resource estimate upgrade, for both lithium and feldspar, to incorporate all 2023 and 2024 drilling, is targeted for the second half of 2024.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Agrees to buy Chronos Therapeutics Ltd for initial GBP899,481, or 1.44 pence per share. Explains price could rise to GBP3.4 million subject to the achievement of certain milestones. Chronos features a neuropsychiatry portfolio including two assets developed to late pre-clinical stage. Further, raises GBP0.85 million via placing and subscription at 1p each. In addition, announces retail offer to raise up to GBP1 million. Proceeds of the fund raise will be used for working capital and to maintain the enlarged group's patent portfolio. Plans name change to TheraCryf PLC.

----------

Impellam Group PLC - Luton, England-based specialist recruitment solutions provider - Says High Court sanctions scheme by which bid from HeadFirst Global BV will be facilitated. Expects scheme to become effective on Thursday, when shares will also be suspended.

----------

Custodian Property Income Reit PLC - real estate investment trust - Shareholders back resolution allowing company to allot shares or grant rights to subscribe for or convert any security into shares in the company in connection with the recommended merger with abrdn Property Income Trust Ltd. Chair David MacLellan says: "The board is pleased with the outcome of the vote, which demonstrated a very strong support from the CREI shareholders and further derisks the execution of the recommended merger." Encourages API shareholders to vote in favour of the scheme.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
11 May 2018 16:43

Nicholas Slater Increases ValiRx Stake To 4.5% From 2.7% (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his

Read more
4 May 2018 17:08

ValiRx Raises GBP950,000 Through Placing To Progress Pipeline (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday it has raised GBP950,000 through the issue of 47.5 million shares at 2.00 pence per share.The clinical stage biotechnology company's down

Read more
25 Apr 2018 13:41

"Major" Milestone As ValiRx's VAL201 Is Granted Patent In EU

LONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.This, it said, follows a US patent which was granted for a a

Read more
19 Apr 2018 12:41

ValiRx Posts Positive Results From VAL101 Compound Pre-Clinical Trials

LONDON (Alliance News) - ValiRx PLC on Thursday said pre-clinical studies showed that its VAL101 compund has a potential to prevent cancer growth at cellular biochemical and genomic molecule is is

Read more
29 Mar 2018 00:12

UPDATE 1-Argentina Merval index to shrink to 28 companies in Q2

BUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31

Read more
28 Mar 2018 23:11

Argentina Merval index to shrink to 28 companies in Q2

BUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31

Read more
20 Mar 2018 13:55

ValirX Gets US Patent For Proposed VAL201 Cancer Treatment

LONDON (Alliance News) - Biotechnology firm ValirX PLC said Tuesday its VAL201 therapeutic compound has been granted a patent in the US.VAL201, which is currently in is

Read more
19 Mar 2018 12:46

YA II CD Lowers ValiRx Interest To Below 3% Threshold (ALLISS)

LONDON (Alliance News) - Life sciences firm ValiRx PLC said on Monday YA II CD Ltd has cut its stake in the company to below 3%.Prior to last Thursday's YA II CD a

Read more
11 Jan 2017 11:18

ValiRx upbeat on positive VAL201 study results

(ShareCast News) - Clinical stage biotechnology company ValiRx announced positive results in its VAL201 personalised Phase l/II prostate cancer study on Wednesday, adding that with accumulation of safety and tolerability data there is also evidence of disease stabilisation on CT imaging and reductio

Read more
11 Jan 2017 09:01

ValiRx To Expand VAL201 Studies After Positive Results

Read more
3 Nov 2016 11:40

ValiRx reports good progress at Georgia drug trial

(ShareCast News) - Life science company focused on clinical stage cancer therapeutic development, ValiRx, updated the market on the clinical development of its novel cancer treatment drug, VAL401. The AIM-traded firm said ValiSeek, the joint venture between ValiRx and Tangent Reprofiling, was formed

Read more
27 Sep 2016 10:17

ValiRx Interim Loss Widens As It Progresses Drug Pipeline

Read more
28 Jul 2016 08:41

ValiRx Gets Patent Coverage For VAL401 In New Zealand

Read more
26 Jul 2016 09:43

ValiRx Issues Shares To Bracknor For Loan Note Conversion (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.